Locations:
Search IconSearch
March 10, 2022/Cancer/Surgical Oncology

Sarcoma Nestled Between Esophagus, Trachea and Aortic Arch: A Case Study

Preoperative chemotherapy enables successful surgical resection

Liposarcoma biopsy under microscopy zoom in different ranges

A 45-year-old woman from Illinois had an enlarging thoracic inlet mass that had been initially identified in 2018 by a local physician and was assumed to be benign. Due to tumor growth, the patient underwent a needle biopsy in Chicago three years later, which revealed a low-grade mesenchymal process.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In early 2021, the patient had a virtual consultation with Daniel Raymond, MD, a thoracic surgeon in the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic, for a second opinion. Her only symptom was mild difficulty swallowing; however, given the size and location of the tumor, Dr. Raymond recommended a second biopsy.

The patient had an ultrasound-guided core needle biopsy in Cleveland Clinic’s Head & Neck Institute in mid-February 2021, which revealed a 7 x 7 x 10 cm myxoid liposarcoma nestled between the esophagus, trachea and aortic arch.

“Because of their rarity, sarcomas are frequently misdiagnosed on biopsy,” says Dr. Raymond. “Most pathologists aren’t experienced in diagnosing sarcomas, so it’s paramount that such cases be evaluated by an expert in soft tissue tumors.” Cleveland Clinic’s soft tissue pathology group is led by Brian Rubin, MD, PhD, Chair of the Robert J. Tomsich Pathology & Laboratory Medicine Institute and an expert in the diagnosis of sarcoma.

Based on the biopsy results, the patient underwent a multidisciplinary evaluation at Cleveland Clinic.

The patient’s initial evaluation revealed a myxoid liposarcoma nestled between the esophagus, trachea and aortic arch.

Preoperative therapy

The case was reviewed by Cleveland Clinic’s sarcoma tumor board, and the team embarked on a treatment plan that included induction chemotherapy and radiation therapy followed by surgical resection.

The patient underwent two cycles of ifosfamide concurrent with a radiation dose of 46 Gy in 23 fractions at her home healthcare facility in Chicago. Afterward, she returned to Cleveland Clinic for surgical resection. Preoperative imaging revealed a significant reduction in the mediastinal mass.

Advertisement

“The patient had a remarkable response to the induction therapy,” says Dr. Raymond. “Her mass decreased to 3 x 2 x 9 cm, which gave us the opportunity to perform a more reasonable oncologic resection.”

Multidisciplinary surgical team

The patient’s tumor was located predominantly in her neck, so a team led by Dr. Raymond and Eric Lamarre, MD, a surgeon in the Head & Neck Institute, performed a collar incision and midline sternotomy. Cardiac and vascular surgeons were available to assist, if necessary.

“We had to skeletonize the patient’s thoracic inlet structures, including the trachea, esophagus, innominate veins and great vessels,” explains Dr. Raymond. “Fortunately, we were able to do so without the need for major vascular resection and reconstruction.” The team was also able to preserve the recurrent laryngeal nerve in the tracheoesophageal groove, thereby circumventing any impairment to the patient’s voice.

The patient had an uncomplicated postoperative course and was discharged on postoperative day 3. She completed four cycles of adjuvant chemotherapy and shows no evidence of recurrent disease.

Dr. Raymond attributes this success to the team’s interdisciplinary collaboration and the patient’s response to preoperative induction chemotherapy.

“We have the advantage of being able to assemble a group of highly skilled clinicians in one room – oncologists, radiologists, pathologists and surgeons,” he says. “We’re able to solve difficult problems by sharing our expertise.”

Two takeaways

Dr. Raymond notes two important points from this case. First, sarcomas are frequently misdiagnosed. Therefore, it’s important to confer with expert pathologists who specialize in soft tissue tumors. Second, there are surgical options for resecting tumors in difficult locations. The patient in this case was told she wasn’t a candidate for tumor resection surgery prior to consulting with Dr. Raymond.

Advertisement

“We frequently see patients who have been told they are not candidates for surgery because their tumors involve different structures or cross barriers – from the abdomen into the chest or the neck into the chest,” explains Dr. Raymond. “These kinds of procedures may initially be too daunting for many surgeons – but, by working together, there are few limits to what our multidisciplinary teams can accomplish.”

Advertisement

Related Articles

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Lobular breast cancer cells
December 22, 2025/Cancer/Innovations
Comprehensive Lobular Breast Cancer Program Addresses Often-Misunderstood Disease

Care paths and research initiatives aim to answer unmet clinical needs

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

church bus tour
December 9, 2025/Cancer/News & Insight
Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

Ad